Literature DB >> 17311509

Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome.

Susanne Hahn1, Werner Kuehnel, Susanne Tan, Karen Kramer, Markus Schmidt, Susanne Roesler, Rainer Kimmig, Klaus Mann, Onno E Janssen.   

Abstract

BACKGROUND: One of the main criteria to establish a diagnosis of polycystic ovary syndrome (PCOS) is hyperandrogenemia. Recent observations suggest that total testosterone may not be a sensitive marker for the detection of androgen excess. The aim of the present study was to compare the value of different androgen determinations for diagnosis of PCOS.
METHODS: Untreated PCOS patients (n=133; mean age 28 years) and healthy control women (n=54; mean age 28 years) were included in the study. Measurements of total testosterone and sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstendione, dehydroepiandrosterone sulfate (DHEAS) and albumin were performed. In addition, the free androgen index (FAI), free and bioavailable testosterone were calculated. Clinical signs of hyperandrogenism were evaluated by physical examination. The area under the receiver operating characteristic curve (AUC-ROC) was used to compare the sensitivity and specificity of different androgen determinations to detect PCOS, defined as clinical hyperandrogenism and irregular cycles compatible with the National Institutes of Health criteria of chronic anovulation and clinical or biochemical hyperandrogenism.
RESULTS: All biochemical parameters of hyperandrogenism were significantly higher in PCOS patients than in controls (all p<0.0001). The highest AUC-ROC was found for bioavailable testosterone (0.852) followed by FAI (0.847) and free testosterone (0.837). Lower AUC-ROC was found for SHBG, total testosterone and androstendione (0.765, 0.799 and 0.706, respectively). When FAI=4.97 was taken as a cutoff value, sensitivity was 71.4% and specificity was 85.2%. A cutoff of 0.78 nmol/L for bioavailable testosterone had even higher sensitivity of 75.9%, but slightly lower specificity of 83.3%. FAI and bioavailable testosterone correlated significantly (all p<0.05) with total testosterone, androstendione, LH/FSH ratio and DHEAS. In addition, free testosterone, bioavailable testosterone and FAI correlated significantly with hirsutism scores, and ovarian volume and follicle count.
CONCLUSIONS: ROC analysis provided evidence that calculated testosterone indices (bioavailable testosterone, FAI, free testosterone) are useful parameters for the discrimination of PCOS patients and healthy controls.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311509     DOI: 10.1515/CCLM.2007.031

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  14 in total

1.  First assessment of menstrual cycle function and reproductive endocrine status in Samoan women.

Authors:  G Lambert-Messerlian; M B Roberts; S S Urlacher; J Ah-Ching; S Viali; M Urbanek; S T McGarvey
Journal:  Hum Reprod       Date:  2011-06-15       Impact factor: 6.918

Review 2.  Oligomenorrhoea in exercising women: a polycystic ovarian syndrome phenotype or distinct entity?

Authors:  Susan Awdishu; Nancy I Williams; Sheila E Laredo; Mary Jane De Souza
Journal:  Sports Med       Date:  2009       Impact factor: 11.136

3.  Validity of serum testosterone, free androgen index, and calculated free testosterone in women with suspected hyperandrogenism.

Authors:  Manal K Al Kindi; Faiza S Al Essry; Fatma S Al Essry; Waad-Allah S Mula-Abed
Journal:  Oman Med J       Date:  2012-11

4.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

5.  Fertility biomarkers to estimate metabolic risks in women with polycystic ovary syndrome.

Authors:  Laura Detti; Heather E Jeffries-Boyd; Lucy J Williams; Michael P Diamond; Rebecca A Uhlmann
Journal:  J Assist Reprod Genet       Date:  2015-11-05       Impact factor: 3.412

6.  Head-To-Head Assessment of Diagnostic Performance of Testosterone Immunoassays in Patients With Polycystic Ovary Syndrome.

Authors:  Andreas N Schüring; Stefan Nolte; Manfred Fobker; Frank Kannenberg; Jerzy-Roch Nofer
Journal:  J Clin Lab Anal       Date:  2015-10-26       Impact factor: 2.352

Review 7.  The management of patients with polycystic ovary syndrome.

Authors:  Channa N Jayasena; Stephen Franks
Journal:  Nat Rev Endocrinol       Date:  2014-07-15       Impact factor: 43.330

8.  Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain.

Authors:  Jamal Golbahar; Maha Al-Ayadhi; Negalla Mohan Das; Khalid Gumaa
Journal:  Int J Womens Health       Date:  2012-05-11

9.  Salivary testosterone measurement in women with and without polycystic ovary syndrome.

Authors:  Thozhukat Sathyapalan; Ahmed Al-Qaissi; Eric S Kilpatrick; Soha R Dargham; Joanne Adaway; Brian Keevil; Stephen L Atkin
Journal:  Sci Rep       Date:  2017-06-15       Impact factor: 4.379

10.  To Assess the Association between Glucose Metabolism and Ectopic Lipid Content in Different Clinical Classifications of PCOS.

Authors:  Christian S Göbl; Johannes Ott; Latife Bozkurt; Michael Feichtinger; Victoria Rehmann; Anna Cserjan; Maike Heinisch; Helmut Steinbrecher; Ivica JustKukurova; Radka Tuskova; Michael Leutner; Elisabeth Vytiska-Binstorfer; Christine Kurz; Andrea Weghofer; Andrea Tura; Christian Egarter; Alexandra Kautzky-Willer
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.